Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2

Cancer

Volumn 115, Issue 2, 2009, Pages 390-398

  Phi, Ji Hoon ^a   Kim, Dong Gyu ^a   Chung, Hyun Tai ^a   Lee, Joongyub ^a   Paek, Sun Ha ^a   Jung, Hee Won ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Gamma knife radiosurgery; Hearing preservation; Neurofibromatosis type 2; Vestibular schwannoma

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER CONTROL; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIAL NEUROPATHY; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HEARING; HUMAN; KAPLAN MEIER METHOD; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SALVAGE THERAPY; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADOLESCENT; ADULT; AGE FACTORS; CRANIAL NERVE NEOPLASMS; DEAFNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; PROGNOSIS; RADIOSURGERY;

EID: 59449095325     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24036     Document Type: Article

References (38)

1. Baser ME, DG RE, Gutmann DH. Neurofibromatosis 2. Curr Opin Neurol. 2003;16:27-33.
2. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6:340- 351.
3. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neu- rofibromatosis 2 tumor suppressor. Cell. 1993;72:791-800.
4. Xiao GH, Chernoff J, Testa JR. NF2: the wizardry of merlin. Genes Chromosomes Cancer. 2003;38:389-399.
5. Samii M, Matthies C, Tatagiba M. Management of vestib- ular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwan- nomas in patients with neurofibromatosis 2. Neurosurgery. 1997;40:696-705.
6. Chan AW, Black P, Ojemann RG, et al. Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. Neurosurgery. 2005;57:60-70.
7. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998;339:1426-1433.
8. Pollock BE, Driscoll CL, Foote RL, et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery. 2006;59:77-85.
9. Kida Y, Kobayashi T, Tanaka T, Mori Y. Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2. Surg Neurol. 2000;53:383-389.
10. Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery. 2007;60:460-468.
11. Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereo- tactic radiosurgery in the management of vestibular schwan- nomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74:1288-1293.
12. Subach BR, Kondziolka D, Lunsford LD, Bissonette DJ, Flickinger JC, Maitz AH. Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofi- bromatosis Type 2. J Neurosurg. 1999;90:815-822.
13. Gardner G, Robertson J H. Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol. 1988;97:55-66.
14. Baser ME, Kuramoto L, Woods R, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet. 2005;42:540-546.
15. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotypel phenotype correlations in type 2 neurofibromato- sis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998;35:450-455.
16. Baldwin D, King T T, Chevretton E, Morrison AW. Bilateral cerebellopontine angle tumors in neurofibromatosis type 2. J Neurosurg. 1991;74:910-915.
17. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br JNeurosurg. 2005;19:5-12.
18. Moffat DA, Quaranta N, Baguley DM, Hardy DG, Chang P. Management strategies in neurofibromatosis type 2. Eur Arch Otorhinolaryngol. 2003;260:12-18.
19. Brackmann DE, Fayad JN, Slattery WH, et al. Early proactive management of vestibular schwannomas in neurofibro- matosis type 2. Neurosurgery. 2001;49:274-280.
20. Doherty J K, Friedman RA. Controversies in building a management algorithm for vestibular schwannomas. Curr Opin Otolaryngol Head Neck Surg. 2006;14:305-313.
21. Andrews DW, Suarez O, Goldman HW, et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at 1 institution. Int J Radiat Oncol Biol Phys. 2001;50:1265-1278.
22. Massick DD, Welling D B, Dodson EE, et al. Tumor growth and audiometric change in vestibular schwannomas managed conservatively. Laryngoscope. 2000;110:1843-1849.
23. Masuda A, Fisher LM, Oppenheimer ML, Iqbal Z, Slattery WH. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol. 2004;25:150-154.
24. Chopra R, Kondziolka D, Niranjan A, Lunsford LD, Flick- inger J C. Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys. 2007;68:845-851.
25. Paek SH, Chung HT, Jeong SS, et al. Hearing preservation after gamma knife stereotactic radiosurgery of vestibular schwannoma. Cancer. 2005;104:580-590.
26. Massager N, Nissim O, Delbrouck C, et al. Irradiation of cochlear structures during vestibular schwannoma radiosur- gery and associated hearing outcome. J Neurosurg. 2007; 107:733-739.
27. Thomas C, Di Maio S, Ma R, et al. Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas: prognostic implications of cochlear dose. J Neurosurg. 2007;107:917-926.
28. Phi JH, Paek SH, Chung HT, et al. Gamma knife surgery and trigeminal schwannoma: is it possible to preserve cranial nerve function? J Neurosurg. 2007;107: 727-732.
29. Pollock BE. Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. Neurosurgery. 2006;58:241-248.
30. Regis J, Pellet W, Delsanti C, et al. Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg. 2002;97:1091-1100.
31. Yu CP, Cheung JY, Leung S, Ho R. Sequential volume mapping for confirmation of negative growth in vestibular schwannomas treated by gamma knife radiosurgery. J Neu- rosurg. 2000;93:82-89.
32. Chung HT, Ma R, Toyota B, Clark B, Robar J, McKenzie M. Audiologic and treatment outcomes after linear accelerator-based stereotactic irradiation for acoustic neuroma. Int J Radiat Oncol Biol Phys. 2004;59:1116-1121.
33. Combs SE, Volk S, Schulz-Ertner D, Huber PE, Thilmann C, Debus J. Management of acoustic neuromas with frac- tionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys. 2005;63:75-81.
34. Fuss M, Debus J, Lohr F, et al. Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. Int J Radiat Oncol Biol Phys. 2000;48:1381-1387.
35. Bari ME, Forster DM, Kemeny AA, Walton L, Hardy D, Anderson JR. Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. Br J Neurosurg. 2002;16:284-289.
36. Thomsen J, Mirz F, Wetke R, Astrup J, Bojsen- Moller M, Nielsen E. Intracranial sarcoma in a patient with neurofi- bromatosis type 2 treated with gamma knife radiosurgery for vestibular schwannoma. Am J Otol. 2000;21:364-370.
37. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43:289-294.
38. Rowe J, Grainger A, Walton L, Radatz M, Kemeny A. Safety of radiosurgery applied to conditions with abnormal tumor suppressor genes. Neurosurgery. 2007;60:860-864.